Dihexa

What is Dihexa?

Dihexa is a small, peptide-like molecule derived from angiotensin IV, a fragment of the hormone system better known for controlling blood pressure. Its chemical name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, and it is also listed as PNB-0408. It was developed by a research group at Washington State University as a possible treatment for Alzheimer's and Parkinson's disease.⁴

In animal work, the developers described it as orally active, able to cross the blood-brain barrier and able to help form new connections between nerve cells.² Those features, plus a widely repeated claim that it is millions of times more potent than a key brain growth factor, made it popular in online nootropic communities.

Dihexa has never been tested in a published human trial. It is sold online as a research chemical for memory, focus and protection against cognitive decline, with no approved medical use anywhere.

How Dihexa works

Brain cells talk to each other through connections called synapses, and losing synapses is a core feature of Alzheimer's disease. Dihexa is thought to boost a growth signal called hepatocyte growth factor, or HGF, at its receptor, c-Met. In the brain this system helps neurons grow branches and form new synapses. The idea is that strengthening it could rebuild some of the connections lost to disease.

In more detail, activating c-Met drives cell growth, cell movement, tissue shaping and the maturation of stem cells into neurons, and protects many cell types from injury. The developers reported that Dihexa stimulates this system to induce dendritic branching and synapse formation.² The original target of angiotensin IV, called the AT4 receptor, has been disputed. One group identified it as an enzyme, insulin-regulated aminopeptidase, while the Washington State group presented evidence that the angiotensin IV system overlaps with HGF and c-Met.⁴ The often-quoted figure of seven orders of magnitude greater potency than BDNF comes from cell-culture assays of synapse formation, not from animal behavior or human data.

What the research shows on Dihexa

All of the evidence comes from cells and animals. The developers' reviews describe Dihexa improving memory consolidation in animal models of Alzheimer's disease² and improving memory and motor problems in rodent models, including models relevant to Parkinson's disease.⁴

An independent 2018 systematic review looked at animal studies of angiotensin IV and its analogs. Of 32 studies that met its criteria, eight of nine studies in animals with induced cognitive deficits found that angiotensin IV or an analog, including Dihexa, improved performance on spatial working memory or avoidance tasks. The authors noted that these peptides worked best when injected directly into the brain's fluid spaces close to the time of learning or testing.³ That is very different from how people take Dihexa.

A 2026 review of therapeutic peptides listed Dihexa among neuroactive compounds acting on the HGF and c-Met pathway, while stressing that clinical trials are lacking.¹

Several limits stand out. Most primary studies come from one laboratory. There are no published human data on how Dihexa is absorbed, how long it lasts, what dose is safe or whether it changes cognition. A related HGF and c-Met modulator, fosgonimeton, developed by a company that grew out of this research program, did not meet its primary endpoint in a mid-stage Alzheimer's trial reported in 2024. That does not test Dihexa itself, but it shows how hard it is to turn this pathway into a working treatment.

Studied for: Cognitive research, Neurodegeneration research.

Dihexa reference data

Dihexa dosage in published research

How Dihexa is used in practice

Dihexa is not prescribed by mainstream clinics, and FDA has restricted it from use in compounding. The legal status box on this page has the details. In practice it is bought from research-chemical vendors as a powder, capsules, oral solutions or skin creams.

Users usually take it by mouth or apply it to the skin, with doses taken from online forums and scaled from rodent studies. Because no human dosing data exist, every regimen is guesswork. Some users report short courses of a few weeks followed by breaks, based on the belief that new synapses persist once formed, an idea that has not been tested in people.

There is no pharmacopeial standard for Dihexa, and research-chemical products are not checked for identity, purity or dose. Buyers have no reliable way to know what they are taking.

Dihexa risks and side effects

The honest answer is that Dihexa's side effects in humans are unknown. Users report headaches and feeling overstimulated, but these reports are anecdotal.

The main theoretical concern is cancer. c-Met is a well-known cancer-related receptor, and overactive HGF and c-Met signaling helps many tumors grow, invade and spread. The same reviews that promote Dihexa describe c-Met activation as stimulating cell division and cell movement.² A drug that boosts this pathway throughout the body, taken repeatedly by people who may have undiagnosed tumors, is a real concern rather than a remote one. People with active or suspected cancer, and anyone who is pregnant, should avoid it.

Other unknowns include effects on blood pressure, interactions with other medicines and long-term effects on the brain. Product contamination adds to these risks.

Reported side effects

Alternatives to Dihexa

Anyone worried about memory decline should start with a medical evaluation. Thyroid problems, vitamin B12 deficiency, depression, sleep apnea, medication side effects and hearing loss can all impair memory and are treatable.

For diagnosed Alzheimer's disease, approved treatments include the cholinesterase inhibitors donepezil, rivastigmine and galantamine, and memantine. For early Alzheimer's with confirmed amyloid, the antibody treatments lecanemab (Leqembi) and donanemab (Kisunla) are FDA-approved and modestly slow decline. For healthy adults, regular aerobic exercise, good sleep, blood pressure control and staying socially and mentally active have the best evidence for protecting cognition.

For people drawn to the HGF and c-Met idea specifically, the legitimate route to an experimental brain drug is a registered clinical trial. Trials provide a known product, a defined dose, safety monitoring and informed consent, none of which a research-chemical purchase offers.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?